October MIMS Update

A look at some of the recent changes to the medicines landscape, with new products, presentations, indications and contraindications New Products Selpercatinib (Retevmo) is an orally available, small molecule inhibitor of the rearranged during transfection (RET) receptor tyrosine kinase. Chromosomal rearrangements involving in-frame fusions of RET with various partners can result in constitutively activated chimeric